Variable | 6 week survival group (N = 86, 84.3%) | 6 week mortality group (N = 16, 15.7%) | OR | 95% CI | P Value |
Age (years)* | 40 (30 - 57) | 50 (26 - 60) |
|
| P = 0.8 |
Gender n (%) Male Female |
68 (79.1) 18 (20.9) |
11 (68.8) 5 (31.2) |
0.85 |
0.18 - 1.96
|
P = 0.4 |
Etiology n (%) Viral Non-viral |
49 (57) 37 (43) |
9 (56.2) 7 (43.8) |
0.97 |
0.33 - 2.85 |
P = 1 |
Comorbidity n (%) Yes No |
12 (14) 74 (86) |
3 (18.8) 13 (81.2) |
|
|
P = 0.7 |
Hypovolemic shock n (%) Present Absent |
24 (27.9) 62 (72.1) |
12 (75) 4 (25) |
7.75 |
2.28 - 26.40 |
P = 0.001 |
Ascites n (%) None/mild Moderate/severe |
53 (61.6) 33 (38.4) |
2 (12.5) 14 (87.5) |
11.24 |
2.4 - 52.7 |
P = 0.001
|
Encephalopathy n (%) Present Absent |
19 (22.1) 67 (77.9) |
7 (43.7) 9 (56.3) |
2.7 |
0.9 - 8.3 |
P = 0.1 |
Active bleeding n (%) | 12 (14) | 4 (25) | 2.06 | 0.6 - 7.4 | P = 0.3 |
Clot on varix at endoscope n (%) | 49 (57) | 7 (43.8) | 0.59 | 0.2 - 1.7 | P = 0.5 |
Hb (mean ± SD) | 7.7 ± 2.2 | 8.8 ± 2.2 |
|
| P = 0.07 |
WBC* | 5.3 (2.9 - 8.3) | 10.9 (6.8 - 15.5) |
|
| P < 0.0001 |
Platelets* | 86 (54.5 - 126.5) | 122.5 (83 - 176.3) |
|
| P = 0.06 |
Albumin (g/dl)* | 2.8 ± 0.6 | 2.4 ± 0.5 |
|
| P = 0.005 |
Bilirubin (mg/dl)* | 1.3 (0.8 - 2.9) | 8.7 (1.4 - 19.1) |
|
| P < 0.0001 |
ALT* | 36 (22 - 55) | 75.5 (37 -147) |
|
| P = 0.02 |
AST* | 42 (27.7 - 64.4) | 116 (67.5 - 235.8) |
|
| P < 0.0001 |
Serum creatinine* | 0.8 (0.6 - 1) | 0.9 (0.6 - 1.4) |
|
| P = 0.3 |
Serum Na* | 136 (132.8 - 139) | 132 (130.3 - 136) |
|
| P = 0.04 |
INR* | 1.3 (1.2 - 1.6) | 2.4 (1.7 - 3.2) |
|
| P < 0.0001 |
CPT score | 7.5 (6.8 - 9) | 11 (8 - 11) |
|
| P < 0.0001 |
CPT score A B C |
21 (24.4) 45 (52.3) 20 (23.3) |
0 (0) 5 (31.2) 11 (68.8) |
|
|
P = 0.001 |
MELD score* | 12.7 (9.3 - 16.2) | 24.7 (19.8 - 31) |
|
| P < 0.0001 |
Systolic blood pressure* | 90 (80 - 100) | 75 (0.0 - 87.5) |
|
| P < 0.0001 |